A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
Daiichi Sankyo
540 participants
May 21, 2024
INTERVENTIONAL
Conditions
Summary
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
12 mg/kg intravenous dose on Day 1 of each 21-day cycle
Topotecan will be administered per local standard-of-care (SoC)
Amrubicin will be administered per local SoC
Lurbinectedin will be administered per local SoC
Locations(229)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06203210